Login to Your Account



Atyr Raises $49M in Venture Round for Rare Disease Drugs

By Jennifer Boggs
Managing Editor

Monday, July 29, 2013
If the industry needed another sign that preclinical-stage firms are making a comeback as hot investment prospects – last week's upsized initial public offering by Agios Therapeutics Inc., for example, met with an impressive trading debut on Wall Street – privately held Atyr Pharma Inc. delivered more promising news Monday, disclosing an oversubscribed $49 million Series D round to support work on its rare disease pipeline.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription